Interleukin-4(38-37)-PE38KDEL

Drug Profile

Interleukin-4(38-37)-PE38KDEL

Alternative Names: cpIL4-PE; IL-4 Superkines™; IL4-EC; IL4-PE; Interleukin-4 Empowered Cytokine™; Interleukin-4 PE38KDEL cytotoxin; Interleukin-4 PE38KDEL immunotoxin; Interleukin-4 Pseudomonas toxin; Interleukin-4-Pseudomonas exotoxin; Interleukin-4-Pseudomonas exotoxin fusion protein; INxin; MDNA 55; NBI-3001; PRX321

Latest Information Update: 06 Mar 2017

Price : $50

At a glance

  • Originator National Institutes of Health (USA); Neurocrine Biosciences
  • Developer Medicenna Therapeutics; Sophiris Bio
  • Class Antineoplastics; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Brain metastases
  • Preclinical Glioma
  • Research Bladder cancer
  • Discontinued Solid tumours

Most Recent Events

  • 02 Mar 2017 Medicenna Therapeutics Inc. has been acquired by Medicenna Therapeutics Corp.
  • 01 Oct 2016 Medicenna Therapeutics initiates a phase II trial for Glioblastoma (Recurrent, Second-line therapy or greater) in USA (NCT02858895)
  • 03 Aug 2016 Medicenna Therapeutics plans a phase II trial for Glioblastoma (Recurrent, Second-line therapy or greater) in USA (NCT02858895)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top